Canaccord Genuity Analysts Give Correvio Pharma (CORV) a $7.00 Price Target
Several other equities analysts have also commented on CORV. Echelon Wealth Partners reissued a buy rating on shares of Correvio Pharma in a report on Wednesday, March 13th. HC Wainwright reissued a buy rating and issued a $10.50 target price on shares of Correvio Pharma in a report on Friday, March 15th. Finally, B. Riley began coverage on shares of Correvio Pharma in a report on Tuesday, December 4th. They issued a buy rating and a $7.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, Correvio Pharma currently has a consensus rating of Buy and an average price target of $8.17.
CORV stock opened at $2.99 on Monday. The company has a debt-to-equity ratio of 6.01, a quick ratio of 2.78 and a current ratio of 3.22. Correvio Pharma has a 12 month low of $1.99 and a 12 month high of $5.24. The stock has a market capitalization of $108.19 million, a price-to-earnings ratio of -3.36 and a beta of 0.67.
Several institutional investors and hedge funds have recently bought and sold shares of CORV. Royce & Associates LP acquired a new stake in shares of Correvio Pharma in the 3rd quarter valued at approximately $1,025,000. ARS Investment Partners LLC acquired a new stake in shares of Correvio Pharma in the 3rd quarter valued at approximately $1,121,000. Renaissance Technologies LLC boosted its stake in shares of Correvio Pharma by 22.1% in the 3rd quarter. Renaissance Technologies LLC now owns 739,248 shares of the company’s stock valued at $2,972,000 after purchasing an additional 133,825 shares in the last quarter. Worth Venture Partners LLC acquired a new stake in shares of Correvio Pharma in the 3rd quarter valued at approximately $173,000. Finally, Essex Investment Management Co. LLC acquired a new stake in shares of Correvio Pharma in the 4th quarter valued at approximately $333,000. Institutional investors own 41.83% of the company’s stock.
About Correvio Pharma
Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.
Featured Story: Federal Reserve
Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.